| DB ID | MyCo_2008 |
| Title | Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis |
| Year | 2015 |
| PMID | 25799044 |
| Fungal Diseases involved | Cryptococcal meningitis |
| Associated Medical Condition | AIDS |
| Genus | Cryptococcus |
| Species | neoformans |
| Organism | Cryptococcus neoformans |
| Ethical Statement | The study was approved by the Research Ethical Board of the Triângulo Mineiro Federal University (protocol #1350). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IL-17A |
| Biomarker Full Name | Interleukin-17A |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | This study was carried out from August 2008 to November 2012 at the Teaching Hospital of Triângulo Mineiro Federal University in Uberaba, Minas Gerais State, Brazil. Thirty out of 38 AIDS-patients aged greater than equal 18 years presenting CM (CM+ HIV+) were prospectively enrolled. Cryptococcal meningitis case was defined on clinical and laboratory features including positive CSF India ink stain, CrAg test and Cryptococcus neoformans culture. Demographic, epidemiological, clinical, laboratory and outcome data were obtained from their medical records. |
| Cohort No. | 38 |
| Age Group | None |
| P Value | p≤0.04 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Cryptococcal meningitis (CM) is a common life-threatening fungal infection in AIDS patients and represents a medical, social and economic high burden due to its unacceptable 60% mortality rate. This occurs particularly in poor-resources settings where most individuals present late HIV diagnosis and severe fungal disease at admission together with a limited access to anti-retroviral (ART) and ideal antifungal therapy. Otherwise, in high-income countries, CM number of cases and mortality rate declined significantly following introduction of more effective ART and a gold standard antifungal therapy. Yearly, at least one million of cryptococcosis cases occur around the world, mostly in HIV infected individuals of whom 620,000 die, predominantly in sub-Saharan Africa where the mortality overpasses that associated to tuberculosis despite the expansion of ART programs and FLZ availability during the last years. Latin America is the third global region with high incidence and a 10-week mortality rate of 30 to 55%. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (Welcozyme, Wellcome diagnostics, Dart ford, Oxford, UK) |
| Assay Data | None |
| Validation Techniques used | ELISA, Western blot |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
